Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement warning letter

This article was originally published in The Tan Sheet

Executive Summary

Supplements such as Viusid, Kalsis and Oncoxin marketed by Birmingham, Ala.-based Beck Network are unapproved new drugs because of claims Kalsis "can halt and even reverse bone loss" and that Oncoxin contains "anti-cancerous agents with proven efficacy in cancer treatments," a July 19 warning letter to the firm states. FDA cited a total of eight products marketed by the firm and also took issue with the claim "clinical studies have proven Viusid is highly effective for treating HIV/AIDS." The firm must respond to the letter within 15 days of receipt...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098519

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel